Welcome

... to the pages of Key Opinions in Medicine (KOM) KOM is a newsletter service delivered by Wiley-Blackwell to update healthcare professionals on new developments across various therapy areas.

KOM began its life with Dermatology and Hematology, but we are constantly trying to broaden our spectrum and grow. We are looking forward to interaction with our readers so please feel free to send questions and comments to us.

Latest Issues

2016 issue 05 Neue Leitlinie zur Behandlung der Aktinischen Keratose

Das Verständnis der Aktinischen Keratose (AK) hat sich dramatisch verändert: So weiß man heute, dass neben den klinisch sichtbaren Hautveränderungen im gesamten sonnenexponierten Hautbereich auch häufig subklinische oder makroskopisch nicht sichtbare Läsionen mit ebenso großem Risikopotential bestehen. Diese Erkenntnis hat ihren Niederschlag in der neuen Europäischen S3-Leitlinie zur Behandlung der AK1 gefunden, in der der Fokus auf die Feldkanzerisierung und deren Behandlung gelegt wird.

Topic: Dermatology issue: 5/2016

Conference KOM 01-2016 DDG KOMPAKT

DDG KOMPAKT 2016

Dermatologie im Alter

Topic: Conference issue: 1/2016

2016 issue 01: Subcutaneous administration of Hepatitis B immunoglobulin

Treatment with Hepatitis B immunoglobulin (HBIg) has greatly

reduced the risk of Hepatitis B (HBV) recurrence after liver transplantation and, together with antiviral therapy, it is now is considered the standard of care. HBIg was originally available as an intravenous infusion then as an intramuscular injection, and a formulation for subcutaneous injection (Zutectra) was introduced in Europe in 2010. Administered weekly in patients after prophylaxis with intravenous HBIg, beginning at least 6 months after transplantation, this has been shown to maintain antibody titres above the threshold regarded as the minimum for effective prevention of HBV reinfection (100 IU/L) with few adverse events.

Topic: Hepatology issue: 1/2016

2016 issue 04 The skin barrier and beyond

Atopic dermatitis (AD) poses an enormous global burden, affecting 15–20% of children and 1–3% of adults worldwide.1 In the UK alone, it is estimated that over 1.2 million children aged <12 years are affected by eczema, and up to 1.75 million GP visits each year may be for children with AD.2 Overall, AD is thought to cost the NHS an estimated annual total of £27.6 million (2008 data).2

Topic: Dermatology issue: 4/2016

2016 issue 03 Topical treatment of actinic keratosis

Faced with the challenge of optimising treatment for individual patients, dermatologists have to address many aspects concerning both patient and disease factors. What is the balance of risk and benefit for this patient? Which drug offers the best prospect of success? Which approach fits best with the patient’s lifestyle? What are the patient’s expectations? The 24th European Academy of Dermatology and Venereology Congress in Copenhagen, Denmark, offered a welcome opportunity to debate topical issues. This report summarises the proceedings of the satellite scientific session ‘AK revealed: the paradigm shift of optimised care for patients’, sponsored by LEO Pharma on 9 October 2015, in which dermatologists debated the role of field therapy versus lesion-directed therapy in the management of actinic keratosis.

Topic: Dermatology issue: 3/2016

Languages

KOM is an international publication that can appear in different languages. We offer our sponsors the option to publish across multiple languages or choose one. Please let us know when you need an issue in another language than the one shown.